Nordic Nanovector has enrolled the final two patients into the second safety cohort of its Phase 1 Archer-1 (LYMRIT 37-07) trial investigating safety and preliminary efficacy of Betalutin (177Lu lilotomab satetraxetan) in combination with rituximab in 2nd-line follicular lymphoma (2L FL).
The dosing regimen in this cohort is a single administration of 15 MBq/kg Betalutin preceded by 40mg lilotomab, followed by 375 mg/m2 rituximab once per week for four weeks. Data from this cohort is expected in H1’2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin/40mg lilotomab.
Add to our understanding of Betalutin use in FL patients
As announced in April 2020, Archer-1 is expected to be paused pending this analysis, which is expected to inform plans for the further development of Betalutin development in 2L FL. The company’s primary focus for its resources is on the timely completion of the Phase 2b PARADIGME trial of Betalutin in 3rd-line FL (3L FL).
“We are pleased to complete patient enrolment into the second safety cohort of Archer-1. We look forward to the results from this cohort in H1’2021, which will add to our understanding of Betalutin use in FL patients. The data will also inform our thinking towards further development strategies for Betalutin in broader FL populations than that being investigated in our PARADIGME trial in 3L FL,” says Christine Wilkinson Blanc, Chief Medical Officer of Nordic Nanovector.
Photo of Christine Wilkinson Blanc: Nordic Nanovector
